Autoimmune diseases, immune modulation, inflammation, and self-tolerance
221 articles
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
Small study tests whether tocilizumab can achieve faster, deeper remission in newly diagnosed rheumatoid arthritis patients.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
Phase 3 trial tests otilimab against standard care in 550 patients who failed previous biologics and JAK inhibitors.
Small study explores how tofacitinib may address chronic pain that persists even when inflammation is controlled in RA patients.
Researchers used blood biomarkers and machine learning to predict which expensive RA treatments work best for individual patients.
NYU study reveals how targeted immune therapy transforms inflammatory responses in rheumatoid arthritis treatment.
Study reveals how inflammation blocks growth hormone production and tests whether etanercept can restore healthy levels in women with RA.
Researchers modified red blood cells to teach the immune system tolerance, potentially ending need for harsh immunosuppressive drugs.
Revolutionary precision immunotherapies use AI and cellular engineering to target lupus at its source, offering hope for durable remission.
HSCT therapy achieves drug-free remission in patients with treatment-resistant autoimmune conditions like lupus and rheumatoid arthritis.
